Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN vs KEPIVANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
Infections caused by susceptible strains of bacteria (e.g., Mycoplasma pneumoniae, Chlamydia trachomatis, Rickettsia species),Acne vulgaris,Periodontitis (as adjunctive therapy),Off-label: Chronic obstructive pulmonary disease exacerbations, malaria prophylaxis
FDA-approved: To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.,Off-label: Prevention of oral mucositis in other cancers; management of acute radiation-induced mucositis.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (Cr Cl <30 m L/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Primarily renally excreted unchanged; minimal hepatic metabolism.
Metabolized via proteolytic degradation; no specific CYP450 involvement.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
50-60% bound to serum proteins
Approximately 95% bound to plasma proteins, primarily albumin.
1.5-2.0 L/kg; indicates extensive tissue penetration
Volume of distribution at steady state (Vd_ss) is approximately 0.2 L/kg, indicating limited extravascular distribution, consistent with a large protein-bound molecule. Does not distribute extensively into tissues.
Oral: 75-80%; Topical: minimal systemic absorption
Subcutaneous administration: Absolute bioavailability is approximately 90% compared to intravenous administration. Not available orally; only given subcutaneously.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12-24 hours; GFR <10 m L/min: administer every 24 hours or avoid.
No dose adjustment is recommended for renal impairment, but monitor serum creatinine.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific dose adjustment for Child-Pugh class A or B; use caution in severe impairment.
25-50 mg/kg/day orally divided every 6 hours; maximum 2 g/day.
Safety and efficacy not established; no recommended pediatric dose.
Initiate at lower end of dosing range due to age-related renal function decline; monitor renal function.
No specific dose adjustment, but consider age-related renal and hepatic function decline.
No FDA boxed warning
None.
Photosensitivity reactions,Esophageal ulceration if taken with insufficient fluids,Pseudotumor cerebri in adults,Pancreatitis,Hepatotoxicity,Renal impairment (accumulation may worsen renal function),Superinfection with resistant organisms
Potential for stimulation of epithelial tumor growth (use caution in patients with non-hematologic malignancies).,Risk of allergic reactions including anaphylaxis.,May cause oral mucosal thickening and dental abnormalities.,Avoid use within 24 hours before or after myelotoxic chemotherapy.
Hypersensitivity to tetracyclines,Pregnancy (second and third trimesters) due to fetal harm,Children under 8 years due to permanent tooth discoloration and enamel hypoplasia,Severe hepatic or renal impairment
Hypersensitivity to palifermin or any excipients.,Concurrent use within 24 hours of myelotoxic chemotherapy.
Avoid dairy products (milk, cheese, yogurt) within 2-3 hours of taking Achromycin, as calcium binds tetracycline and reduces absorption. Also avoid iron-fortified foods, calcium-fortified juices, and high-calcium meals. Take on an empty stomach with a full glass of water; food, especially dairy, decreases absorption by up to 50%.
No specific food interactions have been reported for KEPIVANCE. Maintain adequate nutrition and hydration as recommended by your healthcare provider.
ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure can cause permanent discoloration of deciduous teeth (yellow-gray-brown) due to deposition during calcification, and reversible inhibition of bone growth. Avoid use after the fourth month of pregnancy. Risk of maternal hepatotoxicity if used intravenously in pregnancy.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (IV), which produced exposures approximately 40 and 80 times the human exposure at the recommended clinical dose of 60 mcg/kg/day, based on AUC. However, there are no human data. Risk in first trimester: unknown; second and third trimesters: unknown.
Tetracycline is excreted into breast milk in low concentrations. Theoretical risk of dental discoloration and bone growth suppression in nursing infants, but levels are usually below therapeutic. M/P ratio is approximately 0.5-0.8. Use with caution, especially in infants with prolonged exposure. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding.
It is not known whether palifermin is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from palifermin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No dosage adjustment is recommended for pregnancy; however, use is contraindicated after the first trimester due to risks to the fetus. If essential, use the lowest effective dose for the shortest duration. Intravenous doses should be cautious due to risk of hepatotoxicity; reduce dose in renal impairment.
No pharmacokinetic data in pregnancy. No dose adjustment recommendations are provided for pregnancy; use only if clearly needed.
Achromycin (tetracycline) should be administered on an empty stomach (1 hour before or 2 hours after meals) to ensure adequate absorption. Avoid concurrent use with dairy products, antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate tetracycline and reduce absorption. Tetracycline can cause photosensitivity; advise patients to avoid prolonged sun exposure and use sunscreen. It is contraindicated in pregnancy (risk of hepatotoxicity and fetal bone/teeth discoloration), lactation, and children under 8 years (permanent tooth discoloration and bone growth inhibition). Monitor for signs of superinfection, especially Clostridium difficile-associated diarrhea. Tetracycline may increase the effect of warfarin; monitor INR closely.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor used to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy requiring hematopoietic stem cell support. Administer as a 3-day course of 60 mcg/kg/day IV bolus for 3 consecutive days before and 3 consecutive days after myelotoxic therapy. Must be given at least 24 hours before and after chemotherapy; do not administer within 24 hours of chemotherapy due to risk of enhanced cytotoxicity. Monitor for skin reactions, oral/perioral edema, and taste alteration. Contraindicated in patients with known hypersensitivity to E. coli-derived proteins.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not take with dairy products, antacids, iron supplements, or calcium supplements; separate by at least 2-3 hours.,Avoid excessive sunlight or tanning beds; use sunscreen and wear protective clothing to prevent severe sunburn.,Complete the full course of treatment even if you feel better; do not skip doses.,Notify your doctor immediately if you develop watery or bloody diarrhea, rash, headache, blurred vision, or signs of infection worsening.,Do not use if you are pregnant, planning to become pregnant, or breastfeeding; this medication can harm the unborn baby or nursing infant.,Keep out of reach of children; expired tetracycline can cause kidney damage.
KEPIVANCE reduces the severity and duration of mouth sores caused by high-dose chemotherapy.,It is given as a short intravenous infusion once daily for 3 days before and 3 days after your chemotherapy.,You may experience swelling of the mouth, tongue, or lips; skin rash; or changes in taste. Report these to your healthcare team.,Do not receive KEPIVANCE within 24 hours before or after chemotherapy.,Inform your doctor if you have any allergies, especially to E. coli-derived products.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN vs KEPIVANCE, answered by our medical review team.
ACHROMYCIN is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. KEPIVANCE is a Growth Factor that works by Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN and KEPIVANCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.. The standard adult dose of KEPIVANCE is: 60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN and KEPIVANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN is classified as Category C. ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure ca. KEPIVANCE is classified as Category C. KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.